Redox platforms in cancer drug discovery and development

Current Opinion in Chemical Biology

Volumn 15, Issue 1, 2011, Pages 156-161

  Tew, Kenneth D ^a,b   Townsend, Danyelle M ^a,b  

^a MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^b MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBENZOIC ACID; AMIFOSTINE; ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; ARTEMISININ; CANFOSFAMIDE; DIMESNA; DISULFIRAM; ETACRYNIC ACID; EZATIOSTAT; GLUTATHIONE; ISOTHIOCYANIC ACID DERIVATIVE; MENADIONE; MESNA; NOV 002; THIOL DERIVATIVE; UNCLASSIFIED DRUG;

BREAST CANCER; CANCER THERAPY; CELL PROLIFERATION; COLON CANCER; DRUG MECHANISM; DRUG TARGETING; ESOPHAGUS CANCER; HEMATOPOIETIC STEM CELL; HOMEOSTASIS; HUMAN; IMMUNE RESPONSE; LUNG NON SMALL CELL CANCER; MYELODYSPLASTIC SYNDROME; MYELOPROLIFERATIVE DISORDER; NONHUMAN; OVARY CANCER; OXIDATION REDUCTION REACTION; PROMYELOCYTIC LEUKEMIA; PROTEIN PROCESSING; PROTEIN TARGETING; REVIEW; STEM CELL MOBILIZATION;

ANIMALS; ANTINEOPLASTIC AGENTS; DRUG DISCOVERY; GLUTATHIONE; HUMANS; NEOPLASMS; OXIDATION-REDUCTION;

EID: 79851510296     PISSN: 13675931     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpa.2010.10.016     Document Type: Review

References (47)

1. Gius D., Spitz D.R. Redox signaling in cancer biology. Antioxid Redox Signal 2006, 8:1249-1252.
2. Jones D.P. Radical-free biology of oxidative stress. Am J Physiol Cell Physiol 2008, 295:C849-C868.
3. Townsend D.M., Tew K.D., Tapiero H. The importance of glutathione in human disease. Biomed Pharmacother 2003, 57:145-155.
4. Mathai J.C., Missner A., Kugler P., Saparov S.M., Zeidel M.L., Lee J.K., Pohl P. No facilitator required for membrane transport of hydrogen sulfide. Proc Natl Acad Sci USA 2009, 106:16633-16638.
5. Collman J.P., Ghosh S., Dey A., Decreau R.A. Using a functional enzyme model to understand the chemistry behind hydrogen sulfide induced hibernation. Proc Natl Acad Sci USA 2009, 106:22090-22095.
6. Wang J., Hegele R.A. Genomic basis of cystathioninuria (MIM 219500) revealed by multiple mutations in cystathionine gamma-lyase (CTH). Hum Genet 2003, 112:404-408.
7. Kabil O, Banerjee R: Redox biochemistry of hydrogen sulfide. J Biol Chem 2010, 285:21903-21907.
8. Wondrak G.T. Redox-directed cancer therapeutics: molecular mechanisms and opportunities. Antioxid Redox Signal 2009, 11:3013-3069.
9. Kauvar L.M., Higgins D.L., Villar H.O., Sportsman J.R., Engqvist-Goldstein A., Bukar R., Bauer K.E., Dilley H., Rocke D.M. Predicting ligand binding to proteins by affinity fingerprinting. Chem Biol 1995, 2:107-118.
10. Villar H.O., Kauvar L.M. Amino acid preferences at protein binding sites. FEBS Lett 1994, 349:125-130.
11. Tew K.D. Redox in redux: emergent roles for glutathione S-transferase P (GSTP) in regulation of cell signaling and S-glutathionylation. Biochem Pharmacol 2007, 73:1257-1269.
12. Gate L., Majumdar R.S., Lunk A., Tew K.D. Increased myeloproliferation in glutathione S-transferase pi-deficient mice is associated with a deregulation of JNK and Janus kinase/STAT pathways. J Biol Chem 2004, 279:8608-8616.
13. Adler V., Yin Z., Fuchs S.Y., Benezra M., Rosario L., Tew K.D., Pincus M.R., Sardana M., Henderson C.J., Wolf C.R., et al. Regulation of JNK signaling by GSTp. EMBO J 1999, 18:1321-1334.
14. Raza A., Galili N., Smith S., Godwin J., Lancet J., Melchert M., Jones M., Keck J.G., Meng L., Brown G.L., List A. Phase 1 multicenter dose-escalation study of ezatiostat hydrochloride (TLK199 tablets), a novel glutathione analog prodrug, in patients with myelodysplastic syndrome. Blood 2009, 113:6533-6540.
15. Tew K.D. Glutathione-associated enzymes in anticancer drug resistance. Cancer Res 1994, 54:4313-4320.
16. Vergote I., Finkler N., del Campo J., Lohr A., Hunter J., Matei D., Kavanagh J., Vermorken J.B., Meng L., Jones M., et al. Phase 3 randomised study of canfosfamide (Telcyta, TLK286) versus pegylated liposomal doxorubicin or topotecan as third-line therapy in patients with platinum-refractory or -resistant ovarian cancer. Eur J Cancer 2009, 45:2324-2332.
17. Kavanagh JJ, Levenback CF, Ramirez PT, Wolf JL, Moore CL, Jones MR, Meng L, Brown GL, Bast Jr RC: Phase 2 study of canfosfamide in combination with pegylated liposomal doxorubicin in platinum and paclitaxel refractory or resistant epithelial ovarian cancer. J Hematol Oncol 2010, 3:9.
18. Lo H.W., Ali-Osman F. Structure of the human allelic glutathione S-transferase-pi gene variant, hGSTP1C, cloned from a glioblastoma multiforme cell line. Chem Biol Interact 1998, 111-112:91-102.
19. Stoehlmacher J., Park D.J., Zhang W., Groshen S., Tsao-Wei D.D., Yu M.C., Lenz H.J. Association between glutathione S-transferase P1, T1, and M1 genetic polymorphism and survival of patients with metastatic colorectal cancer. J Natl Cancer Inst 2002, 94:936-942.
20. Netto L.E., de Oliveira M.A., Monteiro G., Demasi A.P., Cussiol J.R., Discola K.F., Demasi M., Silva G.M., Alves S.V., Faria V.G., Horta B.B. Reactive cysteine in proteins: protein folding, antioxidant defense, redox signaling and more. Comp Biochem Physiol C Toxicol Pharmacol 2007, 146:180-193.
21. Priora R., Coppo L., Salzano S., Di Simplicio P., Ghezzi P. Measurement of mixed disulfides including glutathionylated proteins. Methods Enzymol 2010, 473:149-159.
22. Townsend D.M., Manevich Y., He L., Hutchens S., Pazoles C.J., Tew K.D. Novel role for glutathione S-transferase pi, regulator of protein S-glutathionylation following oxidative and nitrosative stress. J Biol Chem 2009, 284:436-445.
23. Fiaschi T., Cozzi G., Raugei G., Formigli L., Ramponi G., Chiarugi P. Redox regulation of beta-actin during integrin-mediated cell adhesion. J Biol Chem 2006, 281:22983-22991.
24. Townsend D.M. S-glutathionylation: indicator of cell stress and regulator of the unfolded protein response. Mol Interv 2007, 7:313-324.
25. Findlay V.J., Townsend D.M., Morris T.E., Fraser J.P., He L., Tew K.D. A novel role for human sulfiredoxin in the reversal of glutathionylation. Cancer Res 2006, 66:6800-6806.
26. Iwasaki H., Suda T. Cancer stem cells and their niche. Cancer Sci 2009, 100:1166-1172.
27. Droge W., Schulze-Osthoff K., Mihm S., Galter D., Schenk H., Eck H.P., Roth S., Gmunder H. Functions of glutathione and glutathione disulfide in immunology and immunopathology. FASEB J 1994, 8:1131-1138.
28. Gelderman K.A., Hultqvist M., Holmberg J., Olofsson P., Holmdahl R. T cell surface redox levels determine T cell reactivity and arthritis susceptibility. Proc Natl Acad Sci USA 2006, 103:12831-12836.
29. Arai F., Yoshihara H., Hosokawa K., Nakamura Y., Gomei Y., Iwasaki H., Suda T. Niche regulation of hematopoietic stem cells in the endosteum. Ann N Y Acad Sci 2009, 1176:36-46.
30. Monick M.M., Samavati L., Butler N.S., Mohning M., Powers L.S., Yarovinsky T., Spitz D.R., Hunninghake G.W. Intracellular thiols contribute to Th2 function via a positive role in IL-4 production. J Immunol 2003, 171:5107-5115.
31. Jeannin P., Delneste Y., Lecoanet-Henchoz S., Gauchat J.F., Life P., Holmes D., Bonnefoy J.Y. Thiols decrease human interleukin (IL) 4 production and IL-4-induced immunoglobulin synthesis. J Exp Med 1995, 182:1785-1792.
32. Jain J., Loh C., Rao A. Transcriptional regulation of the IL-2 gene. Curr Opin Immunol 1995, 7:333-342.
33. Hadzic T., Li L., Cheng N., Walsh S.A., Spitz D.R., Knudson C.M. The role of low molecular weight thiols in T lymphocyte proliferation and IL-2 secretion. J Immunol 2005, 175:7965-7972.
34. Nakamura H., Masutani H., Yodoi J. Redox imbalance and its control in HIV infection. Antioxid Redox Signal 2002, 4:455-464.
35. Capizzi R.L. The preclinical basis for broad-spectrum selective cytoprotection of normal tissues from cytotoxic therapies by amifostine. Semin Oncol 1999, 26(Suppl. 7):3-21.
36. Verschraagen M., Boven E., Zegers I., Hausheer F.H., Van der Vijgh W.J. Pharmacokinetics of BNP7787 and its metabolite mesna in plasma and ascites: a case report. Cancer Chemother Pharmacol 2003, 51:525-529.
37. Fruehauf J.P., Meyskens F.L. Reactive oxygen species: a breath of life or death?. Clin Cancer Res 2007, 13:789-794.
38. Tew K.D. TLK-286: a novel glutathione S-transferase-activated prodrug. Expert Opin Investig Drugs 2005, 14:1047-1054.
39. Ruscoe J.E., Rosario L.A., Wang T., Gate L., Arifoglu P., Wolf C.R., Henderson C.J., Ronai Z., Tew K.D. Pharmacologic or genetic manipulation of glutathione S-transferase P1-1 (GSTpi) influences cell proliferation pathways. J Pharmacol Exp Ther 2001, 298:339-345.
40. Saavedra J.E., Srinivasan A., Buzard G.S., Davies K.M., Waterhouse D.J., Inami K., Wilde T.C., Citro M.L., Cuellar M., Deschamps J.R., et al. PABA/NO as an anticancer lead: analogue synthesis, structure revision, solution chemistry, reactivity toward glutathione, and in vitro activity. J Med Chem 2006, 49:1157-1164.
41. Townsend D.M., Pazoles C.J., Tew K.D. NOV-002, a mimetic of glutathione disulfide. Expert Opin Investig Drugs 2008, 17:1075-1083.
42. Wang Z.Y., Chen Z. Acute promyelocytic leukemia: from highly fatal to highly curable. Blood 2008, 111:2505-2515.
43. Chen Y., Jungsuwadee P., Vore M., Butterfield D.A., St Clair D.K. Collateral damage in cancer chemotherapy: oxidative stress in nontargeted tissues. Mol Interv 2007, 7:147-156.
44. Efferth T. Molecular pharmacology and pharmacogenomics of artemisinin and its derivatives in cancer cells. Curr Drug Targets 2006, 7:407-421.
45. Hail N., Cortes M., Drake E.N., Spallholz J.E. Cancer chemoprevention: a radical perspective. Free Radic Biol Med 2008, 45:97-110.
46. Baker A.F., Dragovich T., Tate W.R., Ramanathan R.K., Roe D., Hsu C.H., Kirkpatrick D.L., Powis G. The antitumor thioredoxin-1 inhibitor PX-12 (1-methylpropyl 2-imidazolyl disulfide) decreases thioredoxin-1 and VEGF levels in cancer patient plasma. J Lab Clin Med 2006, 147:83-90.
47. O'Dwyer P.J., LaCreta F., Nash S., Tinsley P.W., Schilder R., Clapper M.L., Tew K.D., Panting L., Litwin S., Comis R.L., et al. Phase I study of thiotepa in combination with the glutathione transferase inhibitor ethacrynic acid. Cancer Res 1991, 51:6059-6065.